Richi Alberti, PatriciaMartín, María DoloresAndreu Vázquez, CristinaJiménez Díaz, Ana MaríaSteiner, MartinaMuñoz Fernández, Santiago2021-03-102021-03-102021Richi, P., Martín, M. D., Andreu-Vázquez, C., Jiménez-Díaz, A., Steiner, M., & Muñoz-Fernández, S. (2021). Serological response to influenza vaccine in patients with autoimmune inflammatory diseases: Results of RIER study. Medicina Clínica, 156(3), 118–122. https://doi.org/10.1016/j.medcli.2020.04.0250025-77531578-8989http://hdl.handle.net/11268/9905Background: Influenza vaccine is recommended for patients with autoimmune inflammatory diseases (AIID) on biological therapy. Objective: To evaluate whether serological response to Influenza vaccine obtained in patients on biological therapy is similar to that achieved in patients on synthetic disease-modifying anti-rheumatic drugs (DMARDs) and that obtained in healthy controls. Methods: We designed a cohort study in which patients with AIID, 68 on biological therapy and 46 on synthetic DMARDs, as well as 48 healthy controls, were included and vaccinated during the 2015-2016 influenza season. ELISA was used to measure Influenza antigen (Ag) A and B antibodies, before and after vaccination. Results: After vaccination, 88.24% of patients on biologics, 71.74% of those on synthetic DMARDs and 89.58% of healthy controls, presented detectable antibodies against antigen A, while 42.65% of subjects on biologics, 41.30% of those on DMARDs and 54.17% of healthy subjects were seropositive against Ag B. We did not find statistical differences. Conclusions: In our study, biological therapy is not associated with worse serological response.engEnfermedades autoinmunesVacunas contra la InfluenzaPruebas serológicasjournal article10.1016/j.medcli.2020.04.025restricted accessLucha contra las enfermedadesVacunación